ClinicalTrials.gg
CompletedNCT02721966MAXIMISEUpdated Oct 1, 2020Results posted

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

A Phase 3 interventional study of Secukinumab and Secukinumab and Placebo in Axial Psoratic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 94 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
503
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.

Enrollment
6th of 26
503 · median 231
Started
2016
with 4 others
Phase 3
16 of 26
1 open now
Registered
13th of 26
by date
Lead sponsor
17 of 26
Novartis Pharmaceuticals

Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 6th largest by enrollment, is one of 5 that started in 2016, is one of 16 in phase 3, and was the 13th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing secukinumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according to assessment of spondyloarthritis international society (ASAS) recommendations for the treatment of axial spondyloarthritis (AxSpA).

Read the detailed description

In the anlalysis (CSR), there are 498 patients, as 5 patients were mis-randomized, i.e. had randomization number but did never take study medication. So there were 498 participants, and not 503

03

Conditions studied

  • Axial Psoratic Arthritis

Browse trials for

Keywords

  • Assessment of spondyloarthritis international society
  • ASAS
  • axial
  • Psoriatic Arthritis
  • PsA
  • Magnetic resonance imaging
  • MRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed
  • Diagnosis of psoriatic arthritis classified by Classification criteria for psoriatic arthritis (CASPAR) criteria
  • Active spinal disease defined by Bath ankylosing spondylitis disease activity index (BASDAI) score ≥ 4
  • Spinal Pain visual analog scale (VAS) ≥ 40 (on a VAS 100 scale)
  • Inadequate Response to at least 2 non-steroidal anti-inflammatory drugs over a 4 weeks period

Exclusion criteria

Exclusion Criteria:

  • History of exposure to other IL-17 or IL-23 inhibitor biologic drug
  • History of exposure to previous biologic disease modifying anti-rheumatic drugs (DMARDs) (Tumor necrosis factor (TNF) blockers or Ustekinumab)
  • Current treatment with disease modifying anti-rheumatic drugs (DMARDs) other than Methotrexate
  • Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine)
  • Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician

Other protocol-defined inclusion and exclusion criteria may have applied.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
503 participants (actual)

Study arms

  • Experimental
    AIN457 150mg

    Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks

    Biological: Secukinumab

  • Experimental
    AIN457 300mg

    Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks

    Biological: Secukinumab

  • Placebo comparator
    AIN457 Placebo

    Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.

    Biological: Secukinumab · Drug: Secukinumab and Placebo

Interventions

  • BiologicalSecukinumab

    Anti IL-17a monoclonal antibody

    Also known as: AIN457

  • DrugSecukinumab and Placebo

    Placebo matching AIN457

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12

    Purpose of this measure: was to demonstrate that secukinumab 150 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12 after superiority of 300 mg was established ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥10 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)

    Time frame: at week 12

Secondary outcomes

  1. Percentage of Participants With Response to Treatment (150 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12

    Purpose of this key secondary measure: was to demonstrate that secukinumab 150 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12 after superiority of 300 mg was established. 300mg and 150mg are presented side by side for clarity; and to align with protocol. 300mg data is for Primary outcome; and 150mg data is for key secondary outcome ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥10 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)

    Time frame: at week 12

  2. Percentage of Participants With Response to Treatment (150 mg/300 mg AIN457) as Assessed by the ASAS40 Criteria at Week 12

    Proportion of patients with response to treatment as assessed by the Assessment of spondyloarthritis international society (ASAS) 40 criteria at week 12. ASAS40 was defined as an improvement of ≥40% and absolute improvement of ≥20 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)

    Time frame: at week 12

  3. Percentage of Participants With Response to Treatment as Assessed by BASDAI50 at Week 12

    Bath ankylosing spondylitis disease activity index (BASDAI) 50 response BASDAI 50 response is defined as at least 50% improvement (decrease) in total BASDAI score.

    Time frame: at week 12

  4. Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Any Time

    Change from baseline in Spinal pain visual analog scale (VAS) at week 12 VAS is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom,pain,health) orientated from the left (worst) to the right (best). VAS measures pain and stress for on a horizontal line of 100 mm, ranging from very low (0) to very high (100).

    Time frame: at baseline, at week 12

  5. Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Night

    Change from baseline in Spinal pain visual analog scale (VAS) at week 12 VAS is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom,pain,health) orientated from the left (worst) to the right (best). VAS measures pain and stress for on a horizontal line of 100 mm, ranging from very low (0) to very high (100)

    Time frame: at baseline, at week 12

  6. Change From Baseline Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index Score at Week 12

    The Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index score range is 0-16, where 0 is the best outcome, and 16 the worst. The assessor determines whether the site shows tenderness and therefore would count as site with enthesitis. This is done by applying pressure to the site and getting feedback from patient about whether the site is tender.

    Time frame: baseline and week 12

  7. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12

    The health assessment questionnaire disability index (HAQ-DI) assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.

    Time frame: baseline and week 12

  8. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 12

    The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue with a 7-day recall period. Items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52.

    Time frame: baseline and week 12

  9. Change From Baseline in Spondyloarthritis International Society (ASAS) Health Index at Week 12

    Statistical analysis (using ANCOVA) of change from baseline in spondyloarthritis international society (ASAS) Health Index score by visit - treatment period 1 ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors

    Time frame: baseline and week 12

  10. Percentage of Participants With Response to Treatment as Assessed by the ACR20 Criteria at Week 12

    American College of Rheumatology 20% (ACR20) Response at Week 12 is the % of responders with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1)Health Assessment Questionnaire-Disability Index (HAQ-DI), 2)C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGA-VAS)

    Time frame: at week 12

07

Results

Posted Aug 24, 2020

Participant flow

503 participants completed the screening period; and the randomized set consists of 498 patients because 5 participants were misrandomized

Participant flow — Overall Study
MilestoneAIN457 300mgAIN457 150mgPlacebo AIN457 300 mgPlacebo AIN457 150 mgPlacebo
Started16716581805
Completed period 1 & went to period 216215381800
Completed13814272730
Not completed2923975
Withdrew: Protocol violation10000
Withdrew: Withdrawal by subject92370
Withdrew: Adverse event44300
Withdrew: Death10000
Withdrew: Lack of efficacy74000
Withdrew: Lost to follow-up00300
Withdrew: Physician decision11000
Withdrew: Pregnancy10000
Withdrew: Did not continue to period 2512005

Outcome measures

PrimaryPercentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12

Purpose of this measure: was to demonstrate that secukinumab 150 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12 after superiority of 300 mg was established ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥10 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)

Time frame:
at week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12
percentage of participantsAIN457 150mgAIN457 300mgPlacebo AIN457
Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 1266.3 (58.4 to 73.3)62.9 (55.2 to 70.0)31.2 (24.6 to 38.7)
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 4.37 · 95% CI 2.72 to 7.0195% confidence interval for odds ratio
  • AIN457 300mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 3.83 · 95% CI 2.41 to 6.1095% confidence interval for odds ratio
SecondaryPercentage of Participants With Response to Treatment (150 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12

Purpose of this key secondary measure: was to demonstrate that secukinumab 150 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12 after superiority of 300 mg was established. 300mg and 150mg are presented side by side for clarity; and to align with protocol. 300mg data is for Primary outcome; and 150mg data is for key secondary outcome ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥10 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)

Time frame:
at week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment (150 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12
percentage of participantsAIN457 150mgAIN457 300mgPlacebo AIN457
Percentage of Participants With Response to Treatment (150 mg AIN457) as Assessed by the ASAS20 Criteria at Week 1266.3 (58.4 to 73.3)62.9 (55.2 to 70.0)31.2 (24.6 to 38.7)
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 4.37 · 95% CI 2.72 to 7.0195% confidence interval for odds ratio
SecondaryPercentage of Participants With Response to Treatment (150 mg/300 mg AIN457) as Assessed by the ASAS40 Criteria at Week 12

Proportion of patients with response to treatment as assessed by the Assessment of spondyloarthritis international society (ASAS) 40 criteria at week 12. ASAS40 was defined as an improvement of ≥40% and absolute improvement of ≥20 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)

Time frame:
at week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment (150 mg/300 mg AIN457) as Assessed by the ASAS40 Criteria at Week 12
percentage of participantsAIN457 150mgAIN457 300mgPlacebo AIN457
Percentage of Participants With Response to Treatment (150 mg/300 mg AIN457) as Assessed by the ASAS40 Criteria at Week 1239.5 (32.1 to 47.4)43.6 (36.2 to 51.3)12.2 (7.8 to 18.4)
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 4.71 · 95% CI 2.67 to 8.3395% confidence interval for odds ratio
  • AIN457 300mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 5.61 · 95% CI 3.20 to 9.8495% confidence interval for odds ratio
SecondaryPercentage of Participants With Response to Treatment as Assessed by BASDAI50 at Week 12

Bath ankylosing spondylitis disease activity index (BASDAI) 50 response BASDAI 50 response is defined as at least 50% improvement (decrease) in total BASDAI score.

Time frame:
at week 12
Reported as:
Number · percentage of particiapnts
Percentage of Participants With Response to Treatment as Assessed by BASDAI50 at Week 12
percentage of particiapntsAIN457 150mgAIN457 300mgPlacebo AIN457
Percentage of Participants With Response to Treatment as Assessed by BASDAI50 at Week 1232.7 (25.8 to 40.5)37.4 (30.1 to 45.4)9.8 (5.9 to 15.6)
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 4.50 · 95% CI 2.43 to 8.3395% confidence interval for odds ratio
  • AIN457 300mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 5.57 · 95% CI 3.04 to 10.2195% confidence interval for odds ratio
SecondaryChange From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Any Time

Change from baseline in Spinal pain visual analog scale (VAS) at week 12 VAS is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom,pain,health) orientated from the left (worst) to the right (best). VAS measures pain and stress for on a horizontal line of 100 mm, ranging from very low (0) to very high (100).

Time frame:
at baseline, at week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Any Time
scores on a scaleAIN457 150mgAIN457 300mgPlacebo AIN457
Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Any Time-28.5 ± 1.88-26.5 ± 1.84-13.6 ± 1.83
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · ANCOVA · p = <.0001 · Ls mean of treatment difference: -14.9 · 95% CI -20.0 to -9.7
  • AIN457 300mg vs Placebo AIN457 · ANCOVA · p = <.0001 · Ls mean of treatment difference: -12.9 · 95% CI -18.0 to -7.8
SecondaryChange From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Night

Change from baseline in Spinal pain visual analog scale (VAS) at week 12 VAS is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom,pain,health) orientated from the left (worst) to the right (best). VAS measures pain and stress for on a horizontal line of 100 mm, ranging from very low (0) to very high (100)

Time frame:
at baseline, at week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Night
scores on a scaleAIN457 150mgAIN457 300mgPlacebo AIN457
Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Night-30.3 ± 1.95-30.2 ± 1.90-15.2 ± 1.89
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · ANCOVA · p = <.0001 · Ls mean of treatment difference: -15.1 · 95% CI -20.4 to -9.7
  • AIN457 300mg vs Placebo AIN457 · ANCOVA · p = <.0001 · Ls mean of treatment difference: -15.0 · 95% CI -20.3 to -9.8
SecondaryChange From Baseline Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index Score at Week 12

The Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index score range is 0-16, where 0 is the best outcome, and 16 the worst. The assessor determines whether the site shows tenderness and therefore would count as site with enthesitis. This is done by applying pressure to the site and getting feedback from patient about whether the site is tender.

Time frame:
baseline and week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index Score at Week 12
scores on a scaleAIN457 150mgAIN457 300mgPlacebo AIN457
Change From Baseline Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index Score at Week 12-2.2 ± 0.22-2.4 ± 0.21-1.7 ± 0.21
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · ANCOVA · p = 0.0971 · Ls mean of treatment difference: -0.5 · 95% CI -1.1 to 0.1
  • AIN457 300mg vs Placebo AIN457 · ANCOVA · p = 0.0207 · Ls mean of treatment difference: -0.7 · 95% CI -1.3 to -0.1
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12

The health assessment questionnaire disability index (HAQ-DI) assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.

Time frame:
baseline and week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12
scores on a scaleAIN457 150mgAIN457 300mgPlacebo AIN457
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12-0.330 ± 0.0360-0.389 ± 0.0353-0.155 ± 0.0351
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · ANCOVA · p = 0.0005 · Ls mean of treatment difference: -0.175 · 95% CI -0.273 to -0.076
  • AIN457 300mg vs Placebo AIN457 · ANCOVA · p = <.0001 · Ls mean of treatment difference: -0.234 · 95% CI -0.331 to -0.136
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 12

The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue with a 7-day recall period. Items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52.

Time frame:
baseline and week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 12
scores on a scaleAIN457 150mgAIN457 300mgPlacebo AIN457
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 128.0 ± 0.727.6 ± 0.714.2 ± 0.70
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · ANCOVA · p = 0.0002 · Ls mean of treatment difference: 3.8 · 95% CI 1.8 to 5.7
  • AIN457 300mg vs Placebo AIN457 · ANCOVA · p = 0.0007 · Ls mean of treatment difference: 3.4 · 95% CI 1.4 to 5.3
SecondaryChange From Baseline in Spondyloarthritis International Society (ASAS) Health Index at Week 12

Statistical analysis (using ANCOVA) of change from baseline in spondyloarthritis international society (ASAS) Health Index score by visit - treatment period 1 ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors

Time frame:
baseline and week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Spondyloarthritis International Society (ASAS) Health Index at Week 12
scores on a scaleAIN457 150mgAIN457 300mgPlacebo AIN457
Change From Baseline in Spondyloarthritis International Society (ASAS) Health Index at Week 12-2.9 ± 0.29-2.8 ± 0.28-1.2 ± 0.28
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · ANCOVA · p = <.0001 · Ls mean of treatment difference: -1.7 · 95% CI -2.5 to -0.9
  • AIN457 300mg vs Placebo AIN457 · ANCOVA · p = <.0001 · Ls mean of treatment difference: -1.7 · 95% CI -2.4 to -0.9
SecondaryPercentage of Participants With Response to Treatment as Assessed by the ACR20 Criteria at Week 12

American College of Rheumatology 20% (ACR20) Response at Week 12 is the % of responders with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1)Health Assessment Questionnaire-Disability Index (HAQ-DI), 2)C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGA-VAS)

Time frame:
at week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment as Assessed by the ACR20 Criteria at Week 12
percentage of participantsAIN457 150mgAIN457 300mgPlacebo AIN457
Percentage of Participants With Response to Treatment as Assessed by the ACR20 Criteria at Week 1256.5 (47.5 to 65.1)51.6 (43.4 to 59.8)18.5 (13.1 to 25.5)
Statistical analysis
  • AIN457 150mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 5.74 · 95% CI 3.31 to 9.9595% confidence interval for odds ratio
  • AIN457 300mg vs Placebo AIN457 · Regression, Logistic · p = <.0001 · Odds ratio (or): 4.80 · 95% CI 2.83 to 8.1695% confidence interval for odds ratio

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study at week 12. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg1/248 (0.4%)14/248 (5.6%)116/248 (46.8%)
Secukinumab 150 mg0/245 (0%)14/245 (5.7%)108/245 (44.1%)
Placebo0/166 (0%)4/166 (2.4%)47/166 (28.3%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventSecukinumab 300 mgSecukinumab 150 mgPlacebo
GastroenteritisInfections and infestations0/2480/2451/166
PyodermaInfections and infestations0/2480/2451/166
OverdoseInjury, poisoning and procedural complications0/2480/2451/166
LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2480/2451/166
Confusional statePsychiatric disorders0/2480/2451/166
Atrial septal defectCongenital, familial and genetic disorders0/2481/2450/166
Abdominal painGastrointestinal disorders0/2481/2450/166
Crohn's diseaseGastrointestinal disorders0/2481/2450/166
DiverticulumGastrointestinal disorders0/2481/2450/166
Gastritis haemorrhagicGastrointestinal disorders0/2481/2450/166
Most frequent other events
Showing 10 of 27
Most frequent other events
EventSecukinumab 300 mgSecukinumab 150 mgPlacebo
NasopharyngitisInfections and infestations34/24822/24511/166
DiarrhoeaGastrointestinal disorders16/2487/2454/166
Upper respiratory tract infectionInfections and infestations12/24814/2455/166
PharyngitisInfections and infestations7/24813/2455/166
Urinary tract infectionInfections and infestations8/24811/2452/166
BronchitisInfections and infestations11/2489/2451/166
HypertensionVascular disorders4/24810/2452/166
Oropharyngeal painRespiratory, thoracic and mediastinal disorders5/2489/2454/166
RhinitisInfections and infestations9/2485/2450/166
Back painMusculoskeletal and connective tissue disorders9/2486/2456/166

Baseline characteristics

Randomized set: All participants randomized to AIN457 300 mg/150 mg or Placebo.

Age, Categorical
Age, Categorical(Participants)AIN457 300mgAIN457 150mgPlacebo AIN457Total
<=18 years0000
Between 18 and 65 years159156157472
>=65 years89926
Age, Customized
Age, Customized(Participants)AIN457 300mgAIN457 150mgPlacebo AIN457Total
<45 years old776572214
>=45 years old9010094284
Sex: Female, Male
Sex: Female, Male(Participants)AIN457 300mgAIN457 150mgPlacebo AIN457Total
Female908478252
Male778188246
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AIN457 300mgAIN457 150mgPlacebo AIN457Total
Black1001
Asian0022
White162159164485
Unknown46010
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AIN457 300mgAIN457 150mgPlacebo AIN457Total
Hispanic or Latino610925
Not Hispanic or Latino139140146425
Not reported1710835
Unknown55313
08

Study locations

94 sites
  • Novartis Investigative Site
    Brussels, BE-B-1200, Belgium
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Ruse, 7002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1413, Bulgaria
  • Novartis Investigative Site
    Sofia, 1505, Bulgaria
  • Novartis Investigative Site
    Sofia, 1784, Bulgaria
  • Novartis Investigative Site
    Brno, 63800, Czechia
  • Novartis Investigative Site
    Bruntal, 792 01, Czechia
  • Novartis Investigative Site
    Plzen-Bory, 30599, Czechia
  • Novartis Investigative Site
    Uherske Hradiste, 686 01, Czechia
  • Novartis Investigative Site
    Tallinn, 10138, Estonia
  • Novartis Investigative Site
    Tartu, 50406, Estonia
  • Novartis Investigative Site
    Kuopio, 70100, Finland
  • Novartis Investigative Site
    Kuovola, 45100, Finland
  • Novartis Investigative Site
    Strasbourg, Cedex 67098, France
  • Novartis Investigative Site
    Lyon, 69003, France
  • Novartis Investigative Site
    Nantes, 44000, France
  • Novartis Investigative Site
    PARIS Cedex 13, 75651, France
  • Novartis Investigative Site
    Toulouse Cedex, 31059, France
  • Novartis Investigative Site
    Vandoeuvre Les Nancy, 54511, France
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Cottbus, 03042, Germany
  • Novartis Investigative Site
    Hamburg, 22391, Germany
  • Novartis Investigative Site
    Magdeburg, 39110, Germany
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Athens, 12462, Greece
  • Novartis Investigative Site
    Budapest, 1023, Hungary
  • Novartis Investigative Site
    Eger, 3300, Hungary
  • Novartis Investigative Site
    Heviz, 8380, Hungary
  • Novartis Investigative Site
    Miskolc, H-3529, Hungary
  • Novartis Investigative Site
    Veszprem, 8200, Hungary
  • Novartis Investigative Site
    Dublin 8, Ireland
  • Novartis Investigative Site
    Haifa, 343621, Israel
  • Novartis Investigative Site
    Kfar Saba, 44281, Israel
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Bergamo, BG 24128, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Torino, TO 10128, Italy
  • Novartis Investigative Site
    Verona, VR 37134, Italy
  • Novartis Investigative Site
    Bologna, 40138, Italy
  • Novartis Investigative Site
    Bialystok, 15 351, Poland
  • Novartis Investigative Site
    Bydgoszcz, 85 168, Poland
  • Novartis Investigative Site
    Krakow, 31-121, Poland
  • Novartis Investigative Site
    Piotrkow Trybunalski, 97-300, Poland
  • Novartis Investigative Site
    Poznan, 60 529, Poland
  • Novartis Investigative Site
    Poznan, 60-773, Poland
  • Novartis Investigative Site
    Warszawa, 02637, Poland
  • Novartis Investigative Site
    Bucharest, 030167, Romania
  • Novartis Investigative Site
    Bucuresti, 011172, Romania
  • Novartis Investigative Site
    Cluj Napoca, 400006, Romania
  • Novartis Investigative Site
    Izhevsk, 426009, Russian Federation
  • Novartis Investigative Site
    Kazan, 420064, Russian Federation
  • Novartis Investigative Site
    Khanty-Mansiysk, 628012, Russian Federation
  • Novartis Investigative Site
    Kursk, 305007, Russian Federation
  • Novartis Investigative Site
    Moscow, 115093, Russian Federation
  • Novartis Investigative Site
    Moscow, 119049, Russian Federation
  • Novartis Investigative Site
    Moscow, 123182, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, 630099, Russian Federation
  • Novartis Investigative Site
    Orenburg, 460000, Russian Federation
  • Novartis Investigative Site
    Saratov, 410053, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150062, Russian Federation
  • Novartis Investigative Site
    Elche, Alicante 03203, Spain
  • Novartis Investigative Site
    Cordoba, Andalucia 14004, Spain
  • Novartis Investigative Site
    Terrassa, Barcelona 08221, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Salamanca, Castilla Y Leon 37007, Spain
  • Novartis Investigative Site
    Barcelona, Cataluna 08003, Spain
  • Novartis Investigative Site
    Lugo, Galicia 27003, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, Las Palmas De G.C 35020, Spain
  • Novartis Investigative Site
    El Palmar, Murcia 30120, Spain
  • Novartis Investigative Site
    A Coruna, 15006, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Pontevedra, 36001, Spain
  • Novartis Investigative Site
    Sevilla, 41010, Spain
  • Novartis Investigative Site
    Vitoria Gasteiz, 01009, Spain
  • Novartis Investigative Site
    Fribourg, CH 1708, Switzerland
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    St Gallen, CH 9007, Switzerland
  • Novartis Investigative Site
    Zuerich, CH 8091, Switzerland
  • Novartis Investigative Site
    Devon, Barnstaple EX31 4JB, United Kingdom
  • Novartis Investigative Site
    Basingstoke, Hampshire RG24 9NA, United Kingdom
  • Novartis Investigative Site
    Maidstone, Kent ME16 9QQ, United Kingdom
  • Novartis Investigative Site
    Leytonstone, London E11 1NR, United Kingdom
  • Novartis Investigative Site
    Bradford, West Yorkshire BD5 0NA, United Kingdom
  • Novartis Investigative Site
    Leeds, West Yorkshire LS7 4SA, United Kingdom
  • Novartis Investigative Site
    Hull, HU3 2JZ, United Kingdom
  • Novartis Investigative Site
    Wigan, WN6 9EP, United Kingdom
  • Novartis Investigative Site
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Publications

  • Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D'Angelo S, Schulz B, Rissler M, Nagar K, Perella C, Coates LC. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021 May;80(5):582-590. doi: 10.1136/annrheumdis-2020-218808. Epub 2020 Dec 17. PubMed 33334727 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Jun 2019, 32 months.

Results were first posted in Aug 2020, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 32 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2016
First posted
Mar 29, 2016
StartActual
Oct 3, 2016
Primary completionActual
Jun 26, 2019
CompletionActual
Jun 26, 2019
Results first posted
Aug 24, 2020
Last update
Oct 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02721966
Responsible party
Sponsor
First posted
Mar 29, 2016
Start date
Oct 3, 2016
Primary completion
Jun 26, 2019
Completion
Jun 26, 2019
Results posted
Aug 24, 2020
Last update
Oct 1, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion